The Neuroendocrine Tumor Research Foundation (NETRF) continues its aggressive funding of neuroendocrine tumor (NET) research with eight new grants totaling $2.5 million. With this newest round of funding, NETRF expands its portfolio to include research into lung NETs, which affect about one in four NET patients.
NETRF is the leading private funder of neuroendocrine cancer research, funding more than $22 million in NET research since 2005. This latest round of grants leverage some of the latest advancements in cancer:
- CAR T-cell therapy combined with antibody-drug conjugates
- Photodynamic therapy
- Deciphering the impact of mutations in key genes in NETs
- Improving outcomes by combining biomarkers and radiomics
- “Smart” chemotherapy
- Novel SSTR2 radioligands
- Alpha-particle emitting agents for the treatment of lung NETs
- Testing new cancer vaccines on NETs
“We are searching out the best science, identifying dedicated investigators, and asking the right questions with the singular goal of trying to identify new treatments, and better ways to manage the disease,” said Dan Chung, MD, Co-chair, NETRF Board of Scientific Advisors.
“We fund projects that may be translated from the bench to the clinic to make an impact on patient treatment,” said Elyse Gellerman, NETRF Chief Executive Officer.